Indeed, clinically, the combination of atezolizumab (anti-PD-L1) with platinum-based chemotherapy for metastatic non-squamous NSCLC was approved as a first line therapy based on a recent phase III study [44]. Here, CD274 is linked to non-small cell lung carcinoma.